Introducing medication abortion into public sector facilities in KwaZulu-Natal, South Africa: an operations research study
- PMID: 26162575
- DOI: 10.1016/j.contraception.2015.07.001
Introducing medication abortion into public sector facilities in KwaZulu-Natal, South Africa: an operations research study
Abstract
Objectives: Examine the feasibility of introducing mifepristone-misoprostol medication abortion into existing public sector surgical abortion services in KwaZulu-Natal, South Africa.
Study design: Cohort study of women offered medication or surgical abortion in a larger medication abortion introduction study. The sample included 1167 women seeking first-trimester abortion at four public sector facilities; 923 women at ≤9 weeks' gestation were eligible for medication abortion. Women who chose medication abortion took 200 mg of mifepristone orally at the facility and 800 mcg of misoprostol buccally (or vaginally if they anticipated or experienced problems with buccal administration) 48 h later at home, based on international research and global safe abortion guidelines. Women who chose surgical abortion received 600 mg of misoprostol sublingually or vaginally on the day of their procedure followed by manual vacuum aspiration 4 h later. Main outcome measures included proportion of eligible women who chose each method, proportion with complete abortion and proportion reporting adverse events.
Results: Ninety-four percent of eligible women chose medication abortion. No adverse events were reported by women who chose surgical abortion; 3% of women in the medication abortion group reported adverse events and 0.4% reported a serious adverse event. Seventy-six percent of women received a family planning method at the facility where their received their abortion, with no difference based on procedure type. Medication abortion patients were significantly more likely to report they would choose this method again (94% vs. 78%, p<.001) and recommend the method to a friend (98% vs. 84%, p<.001).
Conclusions: Medication abortion was successfully introduced with low and acceptable rates of adverse events; most women at study facilities chose this option.
Implications: Mifepristone-misoprostol medication abortion was successfully integrated into public sector surgical abortion services in South Africa and was chosen by a large majority of women who were eligible and offered choice of early termination method; access to medication abortion should be expanded in South Africa and other similar settings.
Keywords: Acceptability; Medication abortion; Public sector; South Africa.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days.Hum Reprod. 2010 May;25(5):1153-7. doi: 10.1093/humrep/deq037. Epub 2010 Feb 19. Hum Reprod. 2010. PMID: 20172871
-
Acceptability and feasibility of 400 μg buccal misoprostol after 200 mg mifepristone for early medical abortion in Georgia.Eur J Contracept Reprod Health Care. 2016 Oct;21(5):367-71. doi: 10.1080/13625187.2016.1211632. Epub 2016 Jul 22. Eur J Contracept Reprod Health Care. 2016. PMID: 27449873
-
Acceptability and feasibility of the use of 400 μg of sublingual misoprostol after mifepristone for medical abortion up to 63 days since the last menstrual period: evidence from Uzbekistan.Eur J Contracept Reprod Health Care. 2013 Apr;18(2):104-11. doi: 10.3109/13625187.2013.763225. Epub 2013 Feb 7. Eur J Contracept Reprod Health Care. 2013. PMID: 23387475
-
Comparison of vaginal and buccal misoprostol after mifepristone for medication abortion through 70 days of gestation: A retrospective chart review.Contraception. 2022 Nov;115:62-66. doi: 10.1016/j.contraception.2022.06.012. Epub 2022 Jun 28. Contraception. 2022. PMID: 35772525 Review.
-
Elective abortion: Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF).Eur J Obstet Gynecol Reprod Biol. 2018 Mar;222:95-101. doi: 10.1016/j.ejogrb.2018.01.017. Epub 2018 Jan 31. Eur J Obstet Gynecol Reprod Biol. 2018. PMID: 29408754 Review.
Cited by
-
The costs and cost effectiveness of providing first-trimester, medical and surgical safe abortion services in KwaZulu-Natal Province, South Africa.PLoS One. 2017 Apr 3;12(4):e0174615. doi: 10.1371/journal.pone.0174615. eCollection 2017. PLoS One. 2017. PMID: 28369061 Free PMC article.
-
Improving health worker performance of abortion services: an assessment of post-training support to providers in India, Nepal and Nigeria.Reprod Health. 2017 Nov 21;14(1):154. doi: 10.1186/s12978-017-0416-0. Reprod Health. 2017. PMID: 29162119 Free PMC article.
-
Is there a difference in women's experiences of care with medication vs. manual vacuum aspiration abortions? Determinants of person-centered care for abortion services.PLoS One. 2019 Nov 25;14(11):e0225333. doi: 10.1371/journal.pone.0225333. eCollection 2019. PLoS One. 2019. PMID: 31765417 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources